New hope for Hard-to-Treat gut cancers: first human trial launched
Disease control
Completed
This early study tested a new drug called Cabotamig (ARB202) in 33 adults with advanced gastrointestinal cancers (like stomach, liver, or bowel cancer) that had stopped responding to standard treatments. The drug works by targeting a marker called CDH17 on cancer cells and helpin…
Phase: PHASE1 • Sponsor: Arbele Pty Ltd • Aim: Disease control
Last updated May 26, 2026 12:05 UTC